Immediate Impact

55 standout
Sub-graph 1 of 23

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
2025 Standout
3 intermediate papers

Works of Mingjing Shen being referenced

Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway
2019
Inhibition of IL‐6‐JAK/Stat3 signaling in castration‐resistant prostate cancer cells enhances the NK cell‐mediated cytotoxicity via alteration of PD‐L1/NKG2D ligand levels
2017

Author Peers

Author Last Decade Papers Cites
Mingjing Shen 295 243 170 181 29 621
Yong-Nyun Kim 368 188 202 149 23 708
Shenglin Ma 257 177 145 139 29 552
Gang Zhao 330 260 130 106 32 667
Serena De Matteis 272 155 175 114 32 631
Yongri Ouyang 309 178 253 113 25 589
Xueying Wang 233 189 119 109 27 588
Carly Bess Scalise 288 266 127 252 30 654
Olsi Gjyshi 191 156 140 75 23 519
Jianjun Jin 256 188 165 166 32 606
Lei Gong 252 159 157 162 37 658

All Works

Loading papers...

Rankless by CCL
2026